Association of early immune-related adverse events with treatment efficacy of neoadjuvant Toripalimab in resectable advanced non-small cell lung cancer

Association of early immune-related adverse events with treatment efficacy of neoadjuvant Toripalimab in resectable advanced non-small cell lung cancer

BackgroundNeoadjuvant immunotherapy with anti-PD-1 was proved promising in resectable non-small cell lung cancer (NSCLC). Immune-related adverse events (irAEs) have been preliminarily implicated their association with treatment efficacy. Here we elucidated the early onset of irAEs associated with be...

Full description

Bibliographic Details
Main Authors: Ye Tao, Xiang Li, Bing Liu, Jia Wang, Chao Lv, Shaolei Li, Yuzhao Wang, Jinfeng Chen, Shi Yan, Nan Wu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Oncology
Subjects:
immune-related adverse events
neoadjuvant
Toripalimab
non-small cell lung cancer
immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1135140/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1135140/full

Similar Items